VRTX - バ―テックス・ファ―マシュ―ティカルズ (Vertex Pharmaceuticals Incorporated) バ―テックス・ファ―マシュ―ティカルズ

 VRTXのチャート


 VRTXの企業情報

symbol VRTx
会社名 Vertex Pharmaceuticals Inc. (バ―テックス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バーテックス・ファーマシューティカルズ(Vertex Pharmaceuticals Incorporated)は重篤な疾患の治療薬の発見・開発・生産・商品化に従事する会社である。同社は嚢胞性線維症(CF)の治療法の開発と商品化に注力し、他の適応症における研究開発プログラムの推進に取り組んでいる。同社の販売されている医薬品は、ORKAMBIおよびKALYDECOである。ORKAMBI(ivacaftorと組み合わせたlumacaftor)は、その嚢胞性線維症膜貫通コンダクタンス調節因子(CFTR)遺伝子にDelta-F508(F508del)突然変異を2コピー(同型接合)有する患者の治療薬として承認される。KALYDECO(ivacaftor)は、CFTR遺伝子にG551D突然変異または他の特定の突然変異を有するCF患者の治療のために承認されている。CF分野の開発プログラムには、Tezacaftor(VX-661)、VX-152、VX-440、VX-659、VX-445、VX-371などがあります。VX-152、VX-440、VX-659、VX-445はCFTR補正剤である。   バ―テックス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。低分子薬品の発見、開発、製造、商業化に従事する。主要医薬品にはC型肝炎ウイルス治療薬「INCIVEK」と、嚢胞性線維症治療薬「KALYDECO」の2種類がある。その他、自己免疫疾患やインフルエンザ治療用の医薬品の開発にも従事。本社はボストン。   Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
本社所在地 50 Northern Avenue Boston MA 02210 USA
代表者氏名 Jeffrey M. Leiden ジェフリー・M・ライデン
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 617-341-6393
設立年月日 32509
市場名 NASDAQ National Market System
ipoyear 1991年
従業員数 2300人
url www.vrtx.com
nasdaq_url https://www.nasdaq.com/symbol/vrtx
adr_tso
EBITDA EBITDA(百万ドル) 423.58200
終値(lastsale) 185.37
時価総額(marketcap) 47373145892.43
時価総額 時価総額(百万ドル) 44899.32
売上高 売上高(百万ドル) 2622.755
企業価値(EV) 企業価値(EV)(百万ドル) 42724.3
当期純利益 当期純利益(百万ドル) 415.10300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Vertex Pharmaceuticals Incorporated revenues increased 11% to $1.39B. Net income applicable to common stockholders increased 57% to $417.5M. Revenues reflect Product revenues net increase of 40% to $1.39B. Net income benefited from Other income (expense) net increase from $3.1M (expense) to $150.7M (income) Restructuring expenses (income) decrease from $13.5M (expense) to $14K (income).

 VRTXのテクニカル分析


 VRTXのニュース

   Expert Ratings For Vertex Pharmaceuticals  2021/07/01 18:29:28 Business Insider Markets
Within the last quarter, Vertex Pharmaceuticals (NASDAQ: VRTX ) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago
   Molecular Templates Consensus Indicates Potential 108.3% Upside  2021/07/01 10:33:31 DirectorsTalk
Molecular Templates found using ticker (MTEM) now have 7 analysts in total covering the stock. The consensus rating is ''Strong_Buy''. The range between the high target price and low target price is between 34 and 13 and has a mean target at 20.14. Given that the stocks previous close was at 9.67 this indicates there is a potential upside of 108.3%. The 50 day MA is 9.36 and the 200 day MA is 11.37. The market capitalisation for the company is $534m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="MTEM" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Molecular Templates, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies. The company''s lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin''s lymphoma.
   Could Vertex Pharmaceuticals Be a Prime Acquisition Target?  2021/07/01 10:05:00 The Motley Fool
It''s not out of the question.
   Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains- What You Should Know - Yahoo Finance  2021/07/01 04:07:56 Yahoo Finance
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Yahoo Finance
   Raymond James startet Vertex Pharma  2021/06/30 20:30:02 GodmodeTrader
Raymond James startet Vertex Pharma mit Market Perform.
   Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients | Vertex Pharmaceuticals  2021/06/28 19:23:06 CompanyNewsHQ
With this reimbursement agreement more than 1,500 patients now have access to a CFTR modulator therapy for the first View post on CompanyNewsHQ : Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients | Vertex Pharmaceuticals
   Vertex Pharmaceuticals Incorporated: Vertex Announces National Reimbursement Agreement in France for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients  2021/06/28 13:28:00 FinanzNachrichten
- With this reimbursement agreement more than 1,500 patients now have access to a CFTR modulator therapy for the first time Vertex Pharmaceuticals Incorporated(Nasdaq: VRTX) today announced a nati
   BUSINESS WIRE: Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients  2021/06/28 13:27:02 Finanztreff
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.- With this reimbursement agreement more than 1,500 patients now have access to a CFTR modulator therapy for the first time - LONDON --(BUSINESS WIRE)-- 28.06.2021 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)
   Vertex Announces National Reimbursement Agreement in France for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients  2021/06/28 13:26:00 Wallstreet:Online
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced a national reimbursement agreement with the French Health Authorities for the cystic fibrosis (CF) medicines KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor and SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor. Both medicines will be available for all eligible patients once the agreement
   Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients  2021/06/28 13:26:00 Investors Vertex
- With this reimbursement agreement more than 1,500 patients now have access to a CFTR modulator therapy for the first time - LONDON --(BUSINESS WIRE)--Jun. 28, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced a national reimbursement agreement with the French Health
   6 ways to hedge currency risk in foreign equity  2021/05/27 04:19:32 Economic Times India
1,000% return in just 10 years. No, we are not talking about a penny stock or worse, not a Ponzi scheme. This is the kind of returns earned by those investors who invested in the stocks of American mega corporates like Apple, Microsoft, Tesla, and Amazon 10 years ago. That is right, if you had invested Rs 1 lakh in any of these multi-baggers back in 2011, your investment would be worth more than Rs 10 crore today. And now, despite being a pandemic year, the US stock markets closed at record highs in 2020. This has piqued the interest of many Indian investors who are either taking the direct equity route or are using mutual funds to invest in not just the US market but other global markets as well. Many Indian fund houses have even launched mutual fund schemes to cater to this demand. While many of these stocks have returned handsome gains and global equities are a good way to diversify, but before jumping on the bandwagon and putting in the money to invest, one should also be mindful of the risks.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バ―テックス・ファ―マシュ―ティカルズ VRTX Vertex Pharmaceuticals Incorporated)

 twitter  (公式ツイッターやCEOツイッターなど)